Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium
- 11 August 2020
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (10) , e28652
Abstract
Background: Myelodysplastic syndromes (MDS) represent a group of clonal hematopoietic stem cell disorders that commonly progress to acute myeloid leukemia (AML). The diagnostics, prognostics, and treatment of adult MDS are established but do not directly translate to children and adolescents. Pediatric MDS is a rare disease, characterized by unique cytogenetics and histology compared with adult MDS, and often arises secondary to germline predisposition or cytotoxic exposures. Our objective was to highlight aspects of diagnosis/management that would benefit from further systematic review toward the development of clinical practice guidelines for pediatric MDS.Procedure: The North American Pediatric Aplastic Anemia Consortium (NAPAAC) is composed of collaborative institutions with a strong interest in pediatric bone marrow failure syndromes and hematologic malignancies. The NAPAAC MDS working group developed a national survey distributed to 35 NAPAAC institutions to assess data on (1) clinical presentation of pediatric MDS, (2) diagnostic evaluation, (3) criteria for diagnosis, (4) supportive care and treatment decisions, and (5) role of hematopoietic stem cell transplantation (HSCT).Results: Twenty‐eight of 35 institutions returned the survey. Most centers agreed on a common diagnostic workup, though there was considerable variation regarding the criteria for diagnosis. Although there was consensus on supportive care, treatment strategies, including the role of cytoreduction and HSCT, varied across centers surveyed.Conclusions: There is lack of national consensus on diagnosis and treatment of pediatric MDS. This survey identified key aspects of MDS management that will warrant systematic review toward the goal of developing national clinical practice guidelines for pediatric MDS.Keywords
This publication has 17 references indexed in Scilit:
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescentsBlood, 2016
- The current perspective of low-grade myelodysplastic syndrome in childrenInternational Journal of Hematology, 2016
- The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromesHaematologica, 2015
- Pediatric Myelodysplastic SyndromesJournal of Pediatric Hematology/Oncology, 2014
- Advances in the prognostication and management of advanced MDS in childrenBritish Journal of Haematology, 2011
- Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 studyLeukemia, 2011
- Pediatric myelodysplastic syndromesCurrent Treatment Options in Oncology, 2005
- A population‐based study of childhood myelodysplastic syndrome in British Columbia, CanadaBritish Journal of Haematology, 1999
- Clinical practice guidelines in practice and educationJournal of General Internal Medicine, 1997